ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Chroma Progresses Novel Cancer Therapy Into Phase II Clinical Development
Chroma Therapeutics Limited
today announces that its oral, once-daily experimental cancer therapy
CHR-2797 has entered its first Phase II trial, in elderly patients with
treatment refractory acute myeloid leukaemia (AML). Chroma recently
completed a dose- ascending Phase I study where patients with
haematological malignancies were treated for up to three months with
CHR-2797. Encouraging signs of efficacy were noted in a significant
proportion of the AML patients treated.
Ian Nicholson, Chief Executive Officer of Chroma, commented: "We are
pleased that our first-in class agent CHR-2797 is showing clinical benefit
in a challenging patient group and look forward to further elucidating the
potential of this agent as a major new cancer treatment in Phase II
clinical studies."
In addition to being studied in haematological indications, CHR-2797 is
currently being evaluated as a treatment for solid tumours in two Phase I
studies, as monotherapy and in combination with chemotherapy. Chroma plans
to present results from the ongoing Phase I monotherapy study at the
forthcoming American Society of Clinical Oncology (ASCO) scientific meeting
along with further information regarding the mechanism of action of
CHR-2797 at the forthcoming American Association of Cancer Research (AACR)
meeting. Based upon current progress, Chroma anticipates commencing further
Phase II studies with CHR-2797 in solid tumours and haematological
malignancies during 2007. CHR- 2797 was originally licensed from Vernalis
plc.
About aminopeptidases and CHR-2797
Aminopeptidases are a family of intracellular enzymes involved in the
supply of amino acids that are essential for cell growth. Inhibition of
aminopeptidases has been shown to halt cell growth or cause apoptosis (cell
death) in a large number of cancer cell lines. Conversely, normal
(non-tumour) cells have been shown to be less sensitive to aminopeptidase
inhibition. CHR- 2797 is an inhibitor of aminopeptidases that has
demonstrated strong preclinical efficacy as monotherapy and has also been
shown to strongly synergise with a number of leading cancer therapies in a
range of cancer cells.
About Chroma Therapeutics
Chroma Therapeutics, based in Oxford (UK), is a drug discovery and
development company focused in the fields of oncology and inflammatory
disorders. Chroma is building a broad pipeline of first- or best-in-class
treatments utilising its expertise in chromatin biology and its novel
intracellular accumulation technologies, which include the ability to
selectively target drugs to macrophages. Chroma is backed by a number of
leading specialist investors, including Abingworth, Essex Woodlands, Gilde,
Nomura Phase4 and The Wellcome Trust.
Chroma Therapeutics Limited
http://www.chromatherapeutics.com
Chroma progreseazã roman terapie de cancer în faza a II-clinice de dezvoltare - Chroma Progresses Novel Cancer Therapy Into Phase II Clinical Development - articole medicale engleza - startsanatate